Ventripoint appoints Hirson as development VP

Alpha Stox July 20, 2017 Comments Off
Ventripoint appoints Hirson as development VP

Dr. George Adams reports

A THIRD HIGHLY SUCCESSFUL ULTRASOUND EXECUTIVE JOINS VENTRIPOINT

Ventripoint Diagnostics Ltd. has appointed Desmond Hirson as vice-president, development and operations.

“The Ventripoint technology brings a much needed application to cardiac assessment that is accurate, easy to use and relatively inexpensive and fills in a major gap in assessment of the heart,” commented Desmond Hirson.

Desmond Hirson is a seasoned executive and has over 20 years of experience in commercializing medical devices and managing product development, manufacturing operations, regulatory and quality assurance. He has had multiple successes in start-up ventures including three exits at Sonosite Inc, VisualSonics and DICOMIT Inc. Desmond joined VisualSonics in 2003 as Vice President, Engineering , and led a development team to commercialize novel ultrasound technology from prototype to market success in cardiovascular, cancer and other areas of preclinical research that also resulted in ground breaking clinical applications. VisualSonics was purchased by SonoSite, a Seattle based ultrasound company in 2010 followed by the sale of SonoSite and VisualSonics to FUJIFILM of Japan in late 2011. At that time Desmond became Vice President Engineering and General Manager of FUJIFILM VisualSonics. Prior to this Desmond developed ultrasound technology for hospital PACS systems, ultrasound image processing and 3D visualization. Desmond holds a master’s degree in electrical engineering and is co-inventor on a number of patents.

“We welcome Desmond to the team as we continue to address the global opportunity created by the ‘home-country’ approval of the whole-heart VMS-PLUS by Health Canada,” stated Dr. George Adams, CEO of Ventripoint. “Desmond has extensive experience launching ultrasound products, supporting commercialization and modifying products to bring even more customer value and maintaining their best-in-class status.”

The Board of Directors of the Company has issued Mr. Hirson 250,000 option grants each at an exercise price of $.32 for term of 5 years.

We seek Safe Harbor.

Comments are closed.

Newsletterpopup_top_1

Your Name (required)

Your Email (required)

captcha

Newsletterpopup_bottom_1